More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Ritz-Carlton ?Struggling? in the US: President
- Oil Price to Average $75.40 in 2010: Poll
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Obama Reiterates Commitment to Boost US-India Ties
- NBA D-League On The Rise
- Americans Ditch Planes for Trains this Thanksgiving
- Jobless Claims Below 500,000, Durable Orders Slip
- Citi Mortgage Reveals What Treasury Won't
- Topless Business Is Taking Off
- 3 Software Stock Picks from Lazard's Senior Analyst
- Schork Oil Outlook: Gas Bulls Pinning Hopes on Mother Nature
- Toyota Makes Recall Fix And So Long Saab
- Investors Bet on a New Year's Rally For eBay
- Why You Should Play the Reflation Trade: Stock Picker
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Consumer Mood Improves, But Anxiety Over Finances
- Jobless Claims Below 500,000, Durable Orders Slip
- AIG Board OKs CEO Pay; Benmosche Agrees to Stay
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Garlic Price Rises Surpass Gold, Stocks in China
- Americans Ditch Planes for Trains this Thanksgiving
- Oil Price to Average $75.40 in 2010: Poll
- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
- Call Me Crazy: Confessions of a Black Friday Shopper
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com |
In a bear market, shares of ELN [ELN
Loading...
()
]are up a whopping 37 percent over the past month since it and partner Wyeth [WYE
Loading...
()
]announced the basic results of the mid-stage test on their promising Alzheimer's drug. Researchers will get into the nitty-gritty data at the big Alzheimer's conference the end of this month in Chicago. We will be there and yes, dear Elanians, we have requested a live interview with CEO Kelly Martin, but have not received an answer yet.
Anyway, because of the recent run-up in the stock, the Cowen analysts say, "The current valuation implies bap (shorthand for the name of the Alzheimer's drug) sales of $7-$8 billion in 2015. This ultimately may prove conservative, but with minimal topline (the basic clinical trial data released so far) Phase 2 results in-hand and Phase 3 data 2-plus years away, we believe ELN shares have limited near-term upside potential. Therefore, we are initiating coverage of Elan with a Neutral investment rating." Their estimate of peak bap sales actually goes as high as $12 billion in the 2015-2020 timeframe. That's Lipitor money.
Cowen says bap could be a game-changer and the first disease modifying treatment for Alzheimer's, but that it's "too early to draw that conclusion based on the very limited" data available. The analysts believe the detailed test results that will come out in Chicago on Tuesday, July 29th, will be stock-moving. If everything continues to look good, Cowen says WYE and ELN could file for Food and Drug Administration approval of bap as early as December of 2009 and get the green light and launch the drug, under a best-case scenario, by the second half of 2010.
Normally I only print disclosures when they exist, but since this is a big coverage initiation I'm making an exception to my own rule to mention that there are no disclosures listed in the Cowen note.
P.S. My apologies to UBS analyst Roopesh Patel for misspelling his name in yesterday's post about his stock-moving call on Merck[MRK
Loading...
()
].
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes